Clinical Microbiology and Infection, Год журнала: 2022, Номер 29(4), С. 530 - 536
Опубликована: Окт. 28, 2022
Язык: Английский
ASAIO Journal, Год журнала: 2021, Номер 67(5), С. 485 - 495
Опубликована: Фев. 26, 2021
This is an updated guideline from the Extracorporeal Life Support Organization (ELSO) for role of extracorporeal membrane oxygenation (ECMO) patients with severe cardiopulmonary failure due to coronavirus disease 2019 (COVID-19). The great majority COVID-19 (>90%) requiring ECMO have been supported using venovenous (V-V) acute respiratory distress syndrome (ARDS). While run duration may be longer than in non-COVID-19 patients, published mortality appears similar between two groups. However, data collection ongoing, and there a signal that overall increasing. Conventional selection criteria COVID-19-related should used; however, when resources become more constrained during pandemic, stringent contraindications implemented. Formation regional referral networks facilitate communication, resource sharing, expedited patient referral, mobile retrieval. There are no suggest deviation conventional device or management applying patients. Rarely, children require support ARDS, myocarditis, multisystem inflammatory (MIS-C); practices standard. We strongly encourage participation submission investigate optimal use COVID-19.
Язык: Английский
Процитировано
354
Intensive Care Medicine, Год журнала: 2023, Номер 49(2), С. 178 - 190
Опубликована: Фев. 1, 2023
Язык: Английский
Процитировано
146
The Lancet Microbe, Год журнала: 2023, Номер 4(3), С. e179 - e191
Опубликована: Фев. 1, 2023
BackgroundFrequent use of antibiotics in patients with COVID-19 threatens to exacerbate antimicrobial resistance. We aimed establish the prevalence and predictors bacterial infections resistance COVID-19.MethodsWe did a systematic review meta-analysis studies co-infections (identified within ≤48 h presentation) secondary (>48 after outpatients or hospitalised COVID-19. searched WHO Research Database identify cohort studies, case series, case-control trials, randomised controlled trials populations at least 50 published any language between Jan 1, 2019, Dec 2021. Reviews, editorials, letters, pre-prints, conference proceedings were excluded, as which infection was not microbiologically confirmed (or via nasopharyngeal swab only). screened titles abstracts papers identified by our search, then assessed full text potentially relevant articles. reported pooled doing random-effects meta-regression. Our primary outcomes co-infection infection, antibiotic-resistant pathogens among laboratory-confirmed infections. The study protocol registered PROSPERO (CRD42021297344).FindingsWe included 148 362 976 patients, done December, May, 5·3% (95% CI 3·8–7·4), whereas 18·4% (14·0–23·7). 42 (28%) comprehensive data for Among people infections, proportion that resistant antimicrobials 60·8% 38·6–79·3), isolates 37·5% (26·9–49·5). Heterogeneity organisms substantial (I2=95%).InterpretationAlthough infrequently assessed, is highly prevalent Future research surveillance assessing effect on patient population level are urgently needed.FundingWHO.
Язык: Английский
Процитировано
106
BMC Infectious Diseases, Год журнала: 2022, Номер 22(1)
Опубликована: Март 2, 2022
Abstract Background Patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV-2) can develop illness necessitating intensive care admission. Critically ill patients are susceptible for the development of secondary bacterial infections. Due to a combination virus- and drug-induced immunosuppression, critically corona virus disease 2019 (COVID-19) may even have higher risk developing infection. These infections aggravate severity increase death. Further research on in COVID-19 is essential. Therefore, objective this study was investigate incidence associated factors identify most common groups pathogens patients. Methods This mono-center, retrospective observational cohort performed at unit (ICU) Jessa Hospital, Hasselt, Belgium. All adult admitted ICU from 13th March 2020 until 17th October 2020, were eligible inclusion study. Data resulting 116 prospectively entered into customized database. The database retrospectively reviewed three types (secondary pneumonia, bloodstream unknown origin, catheter-related sepsis). Results Of 94 included patients, 68% acquired least one studied during their stay. Almost two thirds (65.96%, n = 62) whereas 29.79% (n 28) bacteremia origin smaller proportion (14.89%, 14) sepsis. Male gender (P 0.05), diabetes mellitus 0.03) cumulative dose corticosteroids 0.004) increased detected cultures pneumonia Gram-negative bacilli. Bacteremia sepsis mostly caused by Gram-positive cocci. Conclusion confirms that very high highest pneumonia. gender, history administration
Язык: Английский
Процитировано
86
Microorganisms, Год журнала: 2022, Номер 10(3), С. 495 - 495
Опубликована: Фев. 23, 2022
While it is reported that COVID-19 patients are more prone to secondary bacterial infections, which strongly linked the severity of complications disease, coinfections associated with not widely studied. This work aimed investigate prevalence and antibiotic resistance profiles among hospitalised patients. Age, gender, weight, identities, sensitivity were collected retrospectively for 108 admitted intensive care unit (ICU) non-ICU ward a single center in Saudi Arabia. ICU (60%) showed significantly higher percentage sputum (74%) blood (38%) samples, compared non-ICU. Acinetobacter baumannii (56%) Klebsiella pneumoniae most prevalent species from patients, presenting full all tested antibiotics except colistin. By contrast, samples exhibited infections Escherichia coli (31%) Pseudomonas aeruginosa (15%) predominantly, elevated E. piperacillin/tazobactam trimethoprim/sulfamethoxazole. alarming correlation between multi-drug resistant coinfection admission requires attention precaution prescribed limit spread bacteria improve therapeutic management.
Язык: Английский
Процитировано
72
Antimicrobial Resistance and Infection Control, Год журнала: 2021, Номер 10(1)
Опубликована: Июнь 4, 2021
During the intensive care units' (ICUs) reorganization that was forced by COVID-19 emergency, attention to traditional infection control measures may have been reduced. Nevertheless, evidence on effect of pandemic healthcare-associated infections (HAIs) is still limited and mixed. In this study, we estimated impact HAI incidence investigated type occurring in patients.
Язык: Английский
Процитировано
93
Annals of Intensive Care, Год журнала: 2021, Номер 11(1)
Опубликована: Май 31, 2021
Abstract Background Dexamethasone decreases mortality in patients with severe coronavirus disease 2019 (COVID-19) and has become the standard of care during second wave pandemic. is an immunosuppressive treatment potentially increasing risk secondary hospital acquired infections critically ill patients. We conducted observational retrospective study three French intensive units (ICUs) comparing first waves pandemic to investigate role dexamethasone occurrence ventilator-associated pneumonia (VAP) blood stream (BSI). Patients admitted from March November 2020 a documented COVID-19 requiring mechanical ventilation (MV) for ≥ 48 h were included. The main outcomes incidence VAP BSI according use dexamethasone. Secondary ventilator-free days (VFD) at day-28 day-60, ICU length stay mortality. Results Among 151 included, 84 received dexamethasone, all but one wave. occurred 63% treated (DEXA+) 57% those not receiving (DEXA−) ( p = 0.43). cumulative VAP, considering death, duration MV late immunosuppression as competing factors was different between groups 0.59). A multivariate analysis did identify independent factor occurrence. (29 vs. 30%; 0.86). DEXA+ had more VFD (9 (0–21) 0 (0–11) days; 0.009) reduced (20 (11–44) 32 (17–46) 0.01). Mortality differ groups. Conclusions In this cohort invasive MV, associated increased or BSI. might explain high rates observed
Язык: Английский
Процитировано
61
Critical Care, Год журнала: 2021, Номер 25(1)
Опубликована: Дек. 1, 2021
Abstract Background Data in the literature about HSV reactivation COVID-19 patients are scarce, and association between HSV-1 mortality remains to be determined. Our objectives were evaluate impact of Herpes simplex virus (HSV) with severe SARS-CoV-2 infections primarily on mortality, secondarily hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) intensive care unit-bloodstream infection (ICU-BSI). Methods We conducted an observational study using prospectively collected data blood respiratory samples from all critically ill a large reference center who underwent tests. Using multivariable Cox cause-specific (cs) models, we investigated or healthcare-associated infections. Results Of 153 admitted for ≥ 48 h Feb-2020 Feb-2021, 40/153 (26.1%) had confirmed (19/61 (31.1%) HSV-positive samples, 36/146 (24.7%) samples. Day-60 was higher (57.5%) versus without (33.6%, p = 0.001). After adjustment risk factors, associated increased (hazard [HR] 2.05; 95% CI 1.16–3.62; 0.01). HAP/VAP occurred 67/153 (43.8%) ICU-BSI 42/153 (27.5%) patients. In reactivation, models showed (csHR 2.38, 1.06–5.39, 0.037), but not ICU-BSI. Conclusions day-60 HAP/VAP.
Язык: Английский
Процитировано
56
Critical Care, Год журнала: 2022, Номер 26(1)
Опубликована: Окт. 18, 2022
Abstract Background The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 non-COVID-19 critically ill patients. Methods We used data from Eurobact II study, a prospective observational multicontinental cohort on HABSI treated in ICU. For current analysis, we selected centers that included both performed descriptive statistics terms patients’ characteristics, source infection microorganism distribution. studied association status mortality using multivariable fragility Cox models. Results A total 53 19 countries over 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) for HABSI. Included comprised 252 (30.4%) 577 (69.6%) time interval hospital admission was similar groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) primary (25.4% 17.2%, 0.006) more frequent had often enterococcal (20.5% 9%) Acinetobacter spp. (18.8% 13.6%) HABSIs. Bacteremic an increased hazard ratio (HR) versus (HR 1.91, 95% CI 1.49–2.45). Conclusions showed differed Enterococcal predominated with elevated risk mortality. Trial registration ClinicalTrials.org number NCT03937245 . Registered 3 May 2019.
Язык: Английский
Процитировано
41
Antibiotics, Год журнала: 2024, Номер 13(2), С. 123 - 123
Опубликована: Янв. 26, 2024
Bloodstream infections (BSIs) arising in the intensive care unit (ICUs) present a significant challenge and we completed narrative review of emerging literature on this issue. Multiple reports document that these are associated with substantial morbidity mortality. Also, they can be caused by variety pathogens. Generally classified as either community or hospital onset, primary secondary origin, microbiology ICU BSIs varies across globe. Gram-positive pathogens predominate certain regions such United States while Gram-negative organisms occur more frequently Europe, Asia, Latin America. The incidence climbed during recent pandemic. complicating persons suffering from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection significantly heighten risk for death compared to patients who develop but not infected SARS-CoV-2. Furthermore, rates antimicrobial resistance generally increasing BSIs. This fact complicates attempts ensure patient receives initially appropriate therapy is particular concern Methicillin-resistant Staphylococcus aureus, Carbapenem-resistant Enterobacterales, Acinetobacter baumannii. Fortunately, respect clinical application, preventive measures exist, analyses suggest increased collaboration between infectious disease specialists intensivists improve outcomes.
Язык: Английский
Процитировано
11